AU2002309038A1 - Compositions for transmucosal administration containing coenzyme Q as the active ingredient - Google Patents

Compositions for transmucosal administration containing coenzyme Q as the active ingredient

Info

Publication number: AU2002309038A1
Authority: AU; Australia
Prior art keywords: compositions; active ingredient; transmucosal administration; administration containing; containing coenzyme
Prior art date: 2001-05-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

AU2002309038A

Other versions

AU2002309038B2 (en

Inventor

Kenji Fujii

Takayoshi Hidaka

Kazunori Hosoe

Taizo Kawabe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kaneka Corp

Original Assignee

Kaneka Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-10

Filing date

2002-05-08

Publication date

2003-05-01

2002-05-08 Application filed by Kaneka Corp filed Critical Kaneka Corp

2002-05-08 Priority claimed from PCT/JP2002/004476 external-priority patent/WO2002092067A1/en

2003-05-01 Publication of AU2002309038A1 publication Critical patent/AU2002309038A1/en

2007-05-17 Application granted granted Critical

2007-05-17 Publication of AU2002309038B2 publication Critical patent/AU2002309038B2/en

2022-05-08 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

AU2002309038A 2001-05-10 2002-05-08 Compositions for transmucosal administration containing coenzyme Q as the active ingredient Ceased AU2002309038B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2001139605		2001-05-10
JP2001-139605		2001-05-10
PCT/JP2002/004476 WO2002092067A1 (en)	2001-05-10	2002-05-08	Compositions for transmucosal administration containing coenzyme q as the active ingredient

Publications (2)

Publication Number	Publication Date
AU2002309038A1 true AU2002309038A1 (en)	2003-05-01
AU2002309038B2 AU2002309038B2 (en)	2007-05-17

Family

ID=18986353

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002309038A Ceased AU2002309038B2 (en)	2001-05-10	2002-05-08	Compositions for transmucosal administration containing coenzyme Q as the active ingredient

Country Status (9)

Country	Link
US (1)	US7754205B2 (en)
EP (1)	EP1388340B1 (en)
KR (2)	KR20060103288A (en)
CN (1)	CN100438862C (en)
AT (1)	ATE480231T1 (en)
AU (1)	AU2002309038B2 (en)
CA (1)	CA2443191A1 (en)
DE (1)	DE60237597D1 (en)
WO (1)	WO2002092067A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3742602B2 (en) *	2001-05-09	2006-02-08	株式会社カネカ	Stable solution of reduced coenzyme Q
TW200304372A (en) *	2002-03-20	2003-10-01	Kanegafuchi Chemical Ind	Compositions for diabetes
TWI322008B (en) *	2003-01-31	2010-03-21	Kaneka Corp	Fatigue improving agent including reduced coenzyme q10
WO2005041945A1 (en) *	2003-10-31	2005-05-12	Kaneka Corporation	Composition containing reduced coenzyme q
WO2005069916A2 (en)	2004-01-22	2005-08-04	University Of Miami	Topical co-enzyme q10 formulations and methods of use
US20090081683A1 (en) *	2005-11-29	2009-03-26	Genelink, Inc.	Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin
EP2005949A1 (en) *	2006-03-13	2008-12-24	Kaneka Corporation	Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent
CN101443010A (en) *	2006-04-10	2009-05-27	三菱瓦斯化学株式会社	Brain function improving agent and functional food containing the same
CA2894933C (en) *	2006-05-02	2017-10-03	University Of Miami	Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
EP1891946A1 (en) *	2006-08-14	2008-02-27	Santhera Pharmaceuticals (Schweiz) AG	Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone
WO2009126764A1 (en)	2008-04-11	2009-10-15	Cytotech Labs, Llc	Methods and use of inducing apoptosis in cancer cells
MX2011011958A (en)	2009-05-11	2012-02-13	Berg Biosystems Llc	METHODS FOR THE TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC CHANGERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES OR ENVIRONMENTAL INFLUENCIATORS.
US20120269867A1 (en)	2011-04-04	2012-10-25	Jimenez Joaquin J	Methods of treating central nervous system tumors
CN102503798B (en) *	2011-11-16	2014-07-16	中国农业科学院蜜蜂研究所	Method for extracting coenzyme Q 10 from bee pollen and application thereof
WO2014088301A1 (en) *	2012-12-03	2014-06-12	가톨릭대학교 산학협력단	Composition for preventing or treating inflammatory diseases or immunological rejection comprising coenzyme q10 as active ingredient
KR101581508B1 (en) *	2012-12-03	2015-12-31	가톨릭대학교 산학협력단	Composition for preventing or treating inflammatory disease or immunological rejection comprising coenzyme Q10 as an effective component
HK1221638A1 (en)	2013-04-08	2017-06-09	博格有限责任公司	Treatment of cancer using coenzyme q10 combination therapies
SG10201907816RA (en)	2013-09-04	2019-09-27	Berg Llc	Methods of treatment of cancer by continuous infusion of coenzyme q10
US20170189350A1 (en)	2015-11-16	2017-07-06	Berg Llc	Methods of treatment of temozolomide-resistant glioma using coenzyme q10
IL320116A (en)	2017-05-17	2025-06-01	Bpgbio Inc	Use of coenzyme Q10 formulations for the treatment and prevention of bullous dermatitis of the skin
US11471426B2 (en)	2019-10-16	2022-10-18	American River Nutrition, Llc	Compositions comprising quinone and/or quinol and methods of preparations and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH655005A5 (en) *	1983-02-16	1986-03-27	Sigma Tau Ind Farmaceuti	PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY ACTION USABLE IN CARDIAC AND VASCULAR THERAPY.
US5378461A (en) *	1991-07-12	1995-01-03	Neigut; Stanley J.	Composition for the topical treatment of skin damage
US5660835A (en) *	1995-02-24	1997-08-26	East Carolina University	Method of treating adenosine depletion
US20020032160A1 (en) *	1995-02-24	2002-03-14	Nyce Jonathan W.	Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
JP3889481B2 (en) *	1996-08-16	2007-03-07	株式会社カネカ	Pharmaceutical composition
US6228891B1 (en) *	1997-02-12	2001-05-08	Mse Pharmazeutika Gmbh	Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
IL122084A (en) *	1997-10-31	1999-09-22	Lurident Ltd	Formulation for personal care with mucoadhesive properties
DE19802050A1 (en)	1998-01-21	1999-07-22	Labtec Gmbh	Peridontal treatment composition providing local oral release of coenzyme Q10
US6048886A (en) *	1998-10-05	2000-04-11	Neigut; Stanley	Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US6200550B1 (en)	1998-12-11	2001-03-13	Q-Pharma, Inc.	Oral care compositions comprising coenzyme Q10
DE19905879A1 (en) *	1999-02-11	2000-08-17	Mse Pharmazeutika Gmbh	Ubiquinon Qn used to treat pain
US20040034107A1 (en)	1999-02-11	2004-02-19	Mse Pharmazeutika Gmbh	Ubiquinone Qn for the treatment of pain
DE19905880A1 (en)	1999-02-11	2000-08-17	Mse Pharmazeutika Gmbh	Spray containing ubiquinone Qn
US8753675B1 (en)	2000-01-20	2014-06-17	Raj K. Chopra	Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
IT1316997B1 (en) *	2000-03-02	2003-05-26	Sigma Tau Healthscience Spa	COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF VASCULOPATHIES, WHICH INCLUDES PROPIONYL L-CARNITINE AND COENZYME Q10.
US6686485B2 (en) *	2001-04-19	2004-02-03	Daniel David West	Synthesis of coenzyme Q10, ubiquinone
JP3742602B2 (en) *	2001-05-09	2006-02-08	株式会社カネカ	Stable solution of reduced coenzyme Q
US7708990B2 (en) *	2004-03-23	2010-05-04	Kaneka Corporation	Coenzyme Q compositions persisting in blood

2002
- 2002-05-08 AU AU2002309038A patent/AU2002309038B2/en not_active Ceased
- 2002-05-08 DE DE60237597T patent/DE60237597D1/en not_active Expired - Lifetime
- 2002-05-08 WO PCT/JP2002/004476 patent/WO2002092067A1/en not_active Ceased
- 2002-05-08 CN CNB028092562A patent/CN100438862C/en not_active Expired - Fee Related
- 2002-05-08 KR KR1020067018328A patent/KR20060103288A/en not_active Ceased
- 2002-05-08 CA CA002443191A patent/CA2443191A1/en not_active Abandoned
- 2002-05-08 AT AT02769547T patent/ATE480231T1/en not_active IP Right Cessation
- 2002-05-08 US US10/476,208 patent/US7754205B2/en active Active
- 2002-05-08 KR KR1020037013595A patent/KR100685696B1/en not_active Expired - Fee Related
- 2002-05-08 EP EP02769547A patent/EP1388340B1/en not_active Expired - Lifetime

Publication	Publication Date	Title
IL162213A0 (en)	2005-11-20	Pharmaceutical compositions containing active vitamin d compounds
AU2002309038A1 (en)	2003-05-01	Compositions for transmucosal administration containing coenzyme Q as the active ingredient
AU781269C (en)	2006-11-30	Pharmaceutical compositions
AU2002313236A1 (en)	2003-05-15	Medicinal compositions
IL161940A0 (en)	2005-11-20	Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
AU2001250420A1 (en)	2001-10-23	Pharmaceutical compositions
AU2002363361A1 (en)	2003-05-19	Pharmaceutical compositions containing oxybutynin
AU2001274307A1 (en)	2002-01-02	Pharmaceutical compositions
AU2002257582A1 (en)	2002-09-04	Pharmaceutical formulation
AU2002238855A1 (en)	2003-03-20	N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002214324A1 (en)	2002-08-08	Medicinal compositions
AU2002340573A1 (en)	2003-05-06	Powdery active ingredient formulations
AU2001273919A1 (en)	2001-10-23	Pharmaceutical compositions
AU4317500A (en)	2001-11-12	Antibiral compositions containing phorbol derivatives as the main active ingredient
AU4431400A (en)	2000-12-05	Anticancer agents containing ep1 antagonists as the active ingredient
AU2002357010A1 (en)	2003-06-17	Stabilized active oxygen compositions
AU2003216503A1 (en)	2003-09-22	Stable pharmaceutical compositions
EP1199076A3 (en)	2003-09-10	Medicament containing tocotrienol as active component
AU2001282541A1 (en)	2002-06-13	Medicinal compositions
HUP0303714A3 (en)	2007-03-28	Pharmaceutical compositions for dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
AU2001242819A1 (en)	2001-10-08	Pharmaceutical compositions containing as the active ingredient nitropyrimidine derivatives or salts thereof
AU2002346223A1 (en)	2003-05-15	Medicinal compositions
AU2001285737A1 (en)	2001-12-24	Pharmaceutical compositions
HK1069117A (en)	2005-05-13	Pharmaceutical compositions comprising active vitamin d compounds
AU2002238875A1 (en)	2002-09-24	Remedies for depression containing ep1 antagonist as the active ingredient